Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B2 | P19099 | 2/20 | 0.36 |
| ▸ | BRD4 | O60885 | 1/20 | 0.30 |
| ▸ | BRD2 | P25440 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Urea SCHEMBL7021643 | 0.80 | BRD4 (0.35) | CYP11B2BRD4BRD2 | |
| SCHEMBL8271343 | 0.79 | MAPK1 (0.38) | BRD4 | |
| SCHEMBL10223701 | 0.79 | BRD4 (0.31) | BRD4BRD2 | |
| SCHEMBL10434632 | 0.77 | BRD4 (0.30) | BRD4BRD2 | |
| SCHEMBL10434750 | 0.77 | BRD4 (0.30) | BRD4BRD2 | |
| SCHEMBL11291689 | 0.77 | CNR2 (0.33) | BRD4BRD2 | |
| SCHEMBL9673399 | 0.74 | — | — | |
| SCHEMBL10434811 | 0.74 | LMNA (0.31) | — | |
| SCHEMBL13208393 | 0.74 | POLB (0.43) | — | |
| SCHEMBL4400264 | 0.74 | CYP1A2 (0.37) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2838531-B1 | INDOLIN-2-ONE DERIVATIVES AS PROTEIN KINASE INHIBITORS | ANNJI PHARM CO LTD (CN) | 2016-09-21 | — | — | EP | claimed |
| US-8946282-B2 | Indolin-2-one derivatives as protein kinase inhibitors | Annji Pharmaceutical Co., Ltd. (TW) | 2015-02-03 | — | — | US | claimed |
| US-20130281451-A1 | INDOLIN-2-ONE DERIVATIVES AS PROTEIN KINASE INHIBITORS | Annji Pharmaceutical Co., Ltd. (TW) | 2013-10-24 | — | — | US | claimed |
| EP-2838531-B1 | INDOLIN-2-ONE DERIVATIVES AS PROTEIN KINASE INHIBITORS | ANNJI PHARM CO LTD (CN) | 2016-09-21 | — | — | EP | disclosed |
| US-8946282-B2 | Indolin-2-one derivatives as protein kinase inhibitors | Annji Pharmaceutical Co., Ltd. (TW) | 2015-02-03 | — | — | US | disclosed |
| US-20130281451-A1 | INDOLIN-2-ONE DERIVATIVES AS PROTEIN KINASE INHIBITORS | Annji Pharmaceutical Co., Ltd. (TW) | 2013-10-24 | — | — | US | disclosed |
| EP-0374756-A2 | Nitrogen-containing cyclic compounds | MERCK PATENT GmbH (DE) | 1990-06-27 | — | — | EP | disclosed |
| EP-0085291-B1 | 2-OXO-1-(AMINOCARBONYLAMINOSULFONYLAMINOCARBONYL)AZETIDINES | E.R. Squibb & Sons, Inc. (US) | 1988-08-17 | — | — | EP | disclosed |
| US-4670553-A | 2-oxo-1-(aminocarbonylaminosulfonyl-aminocarbonyl)azetidines | E. R. SQUIBB & SONS, INC. (US) | 1987-06-02 | — | — | US | disclosed |
| EP-0085291-A1 | 2-Oxo-1-(aminocarbonylaminosulfonylaminocarbonyl)azetidines | E.R. Squibb & Sons, Inc. (US) | 1983-08-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130281451-A1 | INDOLIN-2-ONE DERIVATIVES AS PROTEIN KINASE INHIBITORS | ING2, CDK2, MAP3K20 | CYP11B2 2806/4885BRD4 434/4885BRD2 435/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.